About: Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11
Creator	Lajoie, Christa Matijevic, Mark Chicz, Roman Hedley, Mary Luby, Thomas Urban, Robert
Source	Elsevier; Medline; PMC
abstract	Abstract A phase II trial was conducted in subjects with human papillomavirus (HPV) associated high-grade cervical dysplasia testing the safety and efficacy of a microparticle encapsulated pDNA vaccine. Amolimogene expresses T cell epitopes from E6 and E7 proteins of HPV types 16 and 18. An analysis was performed on a subset of HLA-A2+ subjects to test whether CD8+ T cells specific to HPV 16, 18, 6 and 11 were increased in response to amolimogene immunization. Of the 21 subjects receiving amolimogene, 11 had elevated CD8+ T cell responses to HPV 16 and/or 18 peptides and seven of these also had increases to corresponding HPV 6 and/or 11 peptides. In addition, T cells primed and expanded in vitro with an HPV 18 peptide demonstrated cross-reactivity to the corresponding HPV 11 peptide. These data demonstrate that treatment with amolimogene elicits T cell responses to HPV 16, 18, 6 and 11.
has issue date	2011-12-31(xsd:dateTime)
bibo:doi	10.1016/j.cellimm.2011.04.005
bibo:pmid	21550027
has license	els-covid
sha1sum (hex)	6521e06e489e8afd879a391092ec774d06516e03
schema:url	https://doi.org/10.1016/j.cellimm.2011.04.005
resource representing a document's title	Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11
has PubMed Central identifier	PMC7094646
has PubMed identifier	21550027
schema:publication	Cellular Immunology
resource representing a document's body	covid:6521e06e489e8afd879a391092ec774d06516e03#body_text
is schema:about of	named entity 'T CELLS' named entity 'RESULTS' named entity 'T cells' named entity 'peptides' named entity 'subset' named entity 'HPV' named entity 'encapsulated' named entity 'REGIONS' named entity 'DATA' named entity 'EXPANDED ' named entity 'HLA-A2' named entity 'HPV 18' named entity 'IMMUNIZATION' named entity 'PEPTIDES' named entity 'CROSS' named entity 'INCREASE' named entity 'IMMUNIZATION' named entity 'THESE' named entity 'EFFICACY' named entity 'INCREASED' named entity 'HPV 11' named entity 'CD8' named entity 'PRECURSOR' named entity 'PERFORMED' named entity 'CERVICAL DYSPLASIA' named entity 'PLASMID DNA' named entity 'RESPOND TO' named entity 'A POLY' named entity 'ENCAPSULATED' named entity 'GLYCOLIDE' named entity 'EPITOPES' named entity 'TREATMENT' named entity 'PRIMED' named entity 'EPITOPES' named entity 'HPV TYPES' named entity 'SAFETY' named entity 'MICROPARTICLE' named entity 'INCREASES' named entity 'AMOLIMOGENE' named entity 'DEMONSTRATED' named entity 'HIGH' named entity 'ENCAPSULATED' named entity 'HPV 16' named entity 'HPV' named entity 'ADDITION' named entity 'PROTEINS' named entity 'SPECIFIC' named entity 'SEVEN' named entity 'ASSOCIATED' named entity 'VACCINE' named entity 'RESPONSE TO' named entity 'REACTIVITY' named entity 'IN VITRO' named entity 'HUMAN PAPILLOMAVIRUS ' named entity 'RECEIVING' named entity 'ANALYSIS' named entity 'PDNA' named entity 'GRADE' named entity 'TESTING' named entity 'PEPTIDE' named entity 'RESPONSES' named entity 'TO TEST' named entity 'T CELLS' named entity 'T CELL' named entity 'PHASE II TRIAL' named entity 'FREQUENCY' named entity 'HPV 16' named entity 'ELICITS' named entity 'ELEVATED' named entity 'SUBJECTS' named entity 'SUBSET' covid:arg/6521e06e489e8afd879a391092ec774d06516e03 named entity 'phase II trial' named entity 'HPV' named entity 'T cell' named entity 'demonstrate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software